Pages that link to "Q27678062"

The following pages link to Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans (Q27678062):

Displaying 162 items.

• HIV Genome-Wide Protein Associations: a Review of 30 Years of Research (Q26746070) (← links)
• Harnessing the protective potential of HIV-1 neutralizing antibodies (Q26766153) (← links)
• Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection (Q26775082) (← links)
• The HIV glycan shield as a target for broadly neutralizing antibodies (Q26786540) (← links)
• Recent strategies targeting HIV glycans in vaccine design (Q26823603) (← links)
• Structural insights on the role of antibodies in HIV-1 vaccine and therapy (Q26829461) (← links)
• Antibody responses to envelope glycoproteins in HIV-1 infection (Q26991572) (← links)
• Antibodies in HIV-1 vaccine development and therapy (Q27011574) (← links)
• A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen (Q27302081) (← links)
• Computational Refinement and Validation Protocol for Proteins with Large Variable Regions Applied to Model HIV Env Spike in CD4 and 17b Bound State (Q27303608) (← links)
• SELMA: Selection with Modified Aptamers (Q27343053) (← links)
• Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies (Q27644515) (← links)
• Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer (Q27680496) (← links)
• Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer (Q27680497) (← links)
• The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies (Q27680688) (← links)
• Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign (Q27681806) (← links)
• Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike (Q27683540) (← links)
• Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers (Q27683553) (← links)
• Progress in HIV-1 vaccine development. (Q27693849) (← links)
• Broadly Neutralizing Antibodies for HIV Eradication (Q28073939) (← links)
• Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env (Q28256508) (← links)
• Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope (Q28263655) (← links)
• Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies (Q28263932) (← links)
• Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes (Q28271300) (← links)
• A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies (Q28299280) (← links)
• IDEPI: rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platform (Q28543211) (← links)
• Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy (Q28654490) (← links)
• The Patterns of Coevolution in Clade B HIV Envelope's N-Glycosylation Sites (Q30376065) (← links)
• Current views on the potential for development of a HIV vaccine (Q30397595) (← links)
• Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. (Q30490942) (← links)
• Antigenic and 3D structural characterization of soluble X4 and hybrid X4-R5 HIV-1 Env trimers (Q30580101) (← links)
• Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals (Q33594304) (← links)
• Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys (Q33597744) (← links)
• Antigenicity-defined conformations of an extremely neutralization-resistant HIV-1 envelope spike (Q33620194) (← links)
• HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies (Q33753573) (← links)
• Which Antibody Functions are Important for an HIV Vaccine? (Q33772637) (← links)
• Synthetic carbohydrate antigens for HIV vaccine design (Q33909079) (← links)
• Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization (Q33946158) (← links)
• Differential glycosylation of envelope gp120 is associated with differential recognition of HIV-1 by virus-specific antibodies and cell infection (Q34034659) (← links)
• Structural basis for the recognition of human cytomegalovirus glycoprotein B by a neutralizing human antibody (Q34317887) (← links)
• A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry (Q34509949) (← links)
• Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success (Q34550046) (← links)
• Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo (Q34593860) (← links)
• Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins (Q34721189) (← links)
• Structural evolution of glycan recognition by a family of potent HIV antibodies (Q34782382) (← links)
• Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope (Q34991017) (← links)
• Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions (Q35006601) (← links)
• Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes (Q35076711) (← links)
• A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component (Q35076748) (← links)
• A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene (Q35110976) (← links)
• Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose (Q35119778) (← links)
• Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method (Q35124761) (← links)
• Structure and immune recognition of trimeric pre-fusion HIV-1 Env. (Q35142291) (← links)
• Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer (Q35217426) (← links)
• Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals (Q35585401) (← links)
• Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer (Q35596474) (← links)
• Honing a harder-hitting hammerhead improves broadly neutralizing antibody breadth and potency (Q35836169) (← links)
• Exceptional Antibodies Produced by Successive Immunizations (Q35862420) (← links)
• The INNs and outs of antibody nonproprietary names (Q35881712) (← links)
• A New Approach to Produce HIV-1 Envelope Trimers: BOTH CLEAVAGE AND PROPER GLYCOSYLATION ARE ESSENTIAL TO GENERATE AUTHENTIC TRIMERS (Q35925858) (← links)
• Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection (Q35974269) (← links)
• Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans (Q36079874) (← links)
• Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike (Q36100426) (← links)
• Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env. (Q36104987) (← links)
• Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region (Q36372534) (← links)
• Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies (Q36531018) (← links)
• Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop (Q36694111) (← links)
• Neutralizing Antibody Response and Antibody-Dependent Cellular Cytotoxicity in HIV-1-Infected Individuals from Guinea-Bissau and Denmark (Q36837324) (← links)
• Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcoding (Q36972591) (← links)
• HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds (Q37073506) (← links)
• Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers (Q37123501) (← links)
• Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein (Q37123584) (← links)
• Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency (Q37145901) (← links)
• Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques (Q37171570) (← links)
• Conservation and diversity in the ultralong third heavy-chain complementarity-determining region of bovine antibodies (Q37209384) (← links)
• Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation (Q37318042) (← links)
• HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. (Q37360774) (← links)
• Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding (Q37415418) (← links)
• Natural infection as a blueprint for rational HIV vaccine design (Q37619134) (← links)
• Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. (Q37644030) (← links)
• Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers (Q37695592) (← links)
• Human immunodeficiency virus antibodies and the vaccine problem. (Q38192126) (← links)
• HIV-1 and its resistance to peptidic carbohydrate-binding agents (CBAs): an overview. (Q38291704) (← links)
• Structure and Glycan Binding of a New Cyanovirin-N Homolog (Q38291748) (← links)
• Antibody recognition of HIV and dengue glycoproteins (Q38293417) (← links)
• Engineering broadly neutralizing antibodies for HIV prevention and therapy (Q38717198) (← links)
• Germline-targeting immunogens (Q38764547) (← links)
• Recent advances in synthetic carbohydrate-based human immunodeficiency virus vaccines (Q38780533) (← links)
• Broadly neutralizing antibodies: An approach to control HIV-1 infection (Q38811735) (← links)
• Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV. (Q38924824) (← links)
• Conformational evaluation of HIV-1 trimeric envelope glycoproteins using a cell-based ELISA assay. (Q38950236) (← links)
• Genetic and structural analyses of affinity maturation in the humoral response to HIV-1. (Q38992744) (← links)
• Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers (Q39001126) (← links)
• Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies (Q39001207) (← links)
• Host controls of HIV broadly neutralizing antibody development (Q39108769) (← links)
• The HIV-1 envelope glycoprotein structure: nailing down a moving target (Q39108789) (← links)
• Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies (Q39186163) (← links)
• Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice (Q39407795) (← links)
• Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses (Q40039524) (← links)
• Hidden Lineage Complexity of Glycan-Dependent HIV-1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native-Like gp140 Trimer (Q40061438) (← links)
• Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization (Q40073525) (← links)
• Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection (Q40088529) (← links)
• Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy. (Q40109869) (← links)
• Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope (Q40134111) (← links)
• Structure of Simian Immunodeficiency Virus Envelope Spikes Bound with CD4 and Monoclonal Antibody 36D5. (Q40187598) (← links)
• Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. (Q40276435) (← links)
• Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. (Q40290521) (← links)
• Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives (Q40295939) (← links)
• Enhancing Virion Tethering by BST2 Sensitizes Productively and Latently HIV-infected T cells to ADCC Mediated by Broadly Neutralizing Antibodies. (Q40448856) (← links)
• A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans. (Q40606158) (← links)
• Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design (Q40679052) (← links)
• HIV-1 resistance to neutralizing antibodies: Determination of antibody concentrations leading to escape mutant evolution (Q40940285) (← links)
• Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. (Q41037927) (← links)
• Model Building and Refinement of a Natively Glycosylated HIV-1 Env Protein by High-Resolution Cryoelectron Microscopy (Q41341684) (← links)
• A single gp120 residue can affect HIV-1 tropism in macaques. (Q41930708) (← links)
• Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines (Q41933070) (← links)
• Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. (Q41933482) (← links)
• Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance (Q42148324) (← links)
• Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. (Q42215329) (← links)
• Nanobodies targeting norovirus capsid reveal functional epitopes and potential mechanisms of neutralization. (Q44611786) (← links)
• Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses (Q46202850) (← links)
• Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning (Q46683819) (← links)
• Prediction of HIV-1 sensitivity to broadly neutralizing antibodies shows a trend towards resistance over time. (Q47136810) (← links)
• Integrin α4β7 expression on peripheral blood CD4+ T cells predicts HIV acquisition and disease progression outcomes. (Q47549153) (← links)
• Identification of novel structural determinants in MW965 Env that regulate the neutralization phenotype and conformational masking potential of primary HIV-1 isolates (Q47566053) (← links)
• Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes (Q48133582) (← links)
• Systematic Synthesis and Binding Study of HIV V3 Glycopeptides Reveal the Fine Epitopes of Several Broadly Neutralizing Antibodies. (Q48270835) (← links)
• Exploiting glycan topography for computational design of Env glycoprotein antigenicity. (Q52314288) (← links)
• Structure and Immune Recognition of the HIV Glycan Shield. (Q52338073) (← links)
• A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope. (Q52352443) (← links)
• Global site-specific analysis of glycoprotein N-glycan processing. (Q53068939) (← links)
• Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation. (Q53689028) (← links)
• Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer. (Q54209542) (← links)
• Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies. (Q55003064) (← links)
• Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1 (Q57093617) (← links)
• Mapping of neutralizing antibody epitopes on the envelope of viruses obtained from plasma samples exhibiting broad cross-clade neutralization potential against HIV-1 (Q57452585) (← links)
• Rational Design of DNA-Expressed Stabilized Native-Like HIV-1 Envelope Trimers (Q58721980) (← links)
• Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization (Q58730221) (← links)
• HIV-1 vaccine design through minimizing envelope metastability (Q59339672) (← links)
• Closing and opening holes in the glycan shield of HIV-1 envelope glycoprotein SOSIP trimers can redirect the neutralizing antibody response to the newly unmasked epitopes (Q59349684) (← links)
• Antibody-dependent cellular cytotoxicity in HIV infection (Q59352288) (← links)
• Contribution of the gp120 V3 loop to envelope glycoprotein trimer stability in primate immunodeficiency viruses (Q59358243) (← links)
• Coformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studies (Q59797645) (← links)
• HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design (Q60913187) (← links)
• CD4 occupancy triggers sequential pre-fusion conformational states of the HIV-1 envelope trimer with relevance for broadly neutralizing antibody activity (Q61815651) (← links)
• Oligomannose Glycopeptide Conjugates Elicit Antibodies Targeting the Glycan Core Rather than Its Extremities (Q63362961) (← links)
• Kappa chain maturation helps drive rapid development of an infant HIV-1 broadly neutralizing antibody lineage (Q64053755) (← links)
• Protein and Glycan Mimicry in HIV Vaccine Design. (Q64983102) (← links)
• Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design. (Q64984736) (← links)
• A Systematic Approach to HIV-1 Vaccine Immunogen Selection (Q89708295) (← links)
• The High Content of Fructose in Human Semen Competitively Inhibits Broad and Potent Antivirals that Target High-mannose Glycans (Q89899074) (← links)
• Proteins mimicking epitope of HIV-1 virus neutralizing antibody induce virus-neutralizing sera in mice (Q90211541) (← links)
• Minding the gap: The impact of B-cell tolerance on the microbial antibody repertoire (Q90323195) (← links)
• Antibody responses to the HIV-1 envelope high mannose patch (Q90677040) (← links)
• Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial (Q91620204) (← links)
• Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics (Q91886630) (← links)
• The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1 (Q92188831) (← links)
• A glycan shield on chimpanzee CD4 protects against infection by primate lentiviruses (HIV/SIV) (Q92198323) (← links)
• Antibody responses to viral infections: a structural perspective across three different enveloped viruses (Q92461201) (← links)
• Conformational Engineering of HIV-1 Env Based on Mutational Tolerance in the CD4 and PG16 Bound States (Q92511072) (← links)
• CD4 binding loop responsible for the neutralization of human monoclonal neutralizing antibody Y498 (Q94939084) (← links)
• Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates (Q99633770) (← links)